Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target
Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside.
The brokerage is bullish on the company’s integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29.
Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key risks.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on economictimes.indiatimes.com — the content belongs to The Economic Times.
